We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: J&J COVID-19 Vaccine Associated With Slight Risk of Guillain-Barre Syndrome
FDA: J&J COVID-19 Vaccine Associated With Slight Risk of Guillain-Barre Syndrome
The FDA has found a small — but statistically significant — association between Guillain-Barre Syndrome (GBS) and Johnson & Johnson’s (J&J) COVID-19 vaccine, Ad26.COV2.S.